SSX2IP expression indicates survival rates in AML patients who lack cytogenetic abnormalities. (A) In patients with a normal karyotype, elevated SSX2IP was associated with significantly improved survival rates (log-rank test, P = .007). (B) The expression of all 3 (RHAMM, Survivin, and SSX2IP) LAAs above the median was associated with significantly extended survival times in patients with a normal karyotype, compared with having elevated expression of 2 or fewer of these LAAs (0, 1, or 2; log-rank test, P = .021). The x-axis shows days alive over a 5-year follow-up period and the y-axis indicates probability of survival.